Exchange Traded Concepts LLC Reduces Stock Position in Amgen Inc. $AMGN

Key Points

• Exchange Traded Concepts LLC reduced its stake in Amgen by 64.9% in Q4, selling 40,898 shares and finishing the period with 22,119 shares worth $7.24 million.
• Analysts' coverage is mixed but the consensus rating is "Hold" with a consensus price target of $354.60, though several firms recently raised their targets and ratings.
• Amgen beat Q results (EPS $5.29 vs. $4.76 est.; revenue $9.87B vs. $9.46B), set FY2026 guidance of 21.60–23.00 EPS, and announced a quarterly dividend of $2.52 ($10.08 annual, ~2.9% yield; ex-dividend May 15).

Exchange Traded Concepts LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 64.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,119 shares of the medical research company's stock after selling 40,898 shares during the period. Exchange Traded Concepts LLC's holdings in Amgen were worth $7,240,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company's stock valued at $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC boosted its position in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company's stock worth $331,000 after acquiring an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its stake in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company's stock worth $7,220,000 after acquiring an additional 5,853 shares during the period. Elevation Point Wealth Partners LLC raised its holdings in Amgen by 15.2% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 857 shares of the medical research company's stock valued at $239,000 after acquiring an additional 113 shares during the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC raised its holdings in Amgen by 12.8% in the 2nd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 4,245 shares of the medical research company's stock valued at $1,185,000 after acquiring an additional 481 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. HSBC restated a "buy" rating and set a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. UBS Group upped their target price on Amgen from $380.00 to $390.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Cantor Fitzgerald increased their target price on Amgen from $315.00 to $350.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 4th. Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 19th. Finally, Freedom Capital cut Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $354.60.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $348.77 on Monday. The stock has a market capitalization of $188.01 billion, a PE ratio of 24.51, a P/E/G ratio of 3.46 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a fifty day moving average of $362.59 and a 200-day moving average of $330.59. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the company posted $5.31 EPS. The business's quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is 70.84%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.